KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Current Liabilities (2016 - 2025)

Arbutus Biopharma's Total Current Liabilities history spans 15 years, with the latest figure at $5.2 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 72.6% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $5.2 million, down 72.6%, while the annual FY2024 figure was $15.6 million, 30.55% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $5.2 million at Arbutus Biopharma, up from $5.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $32.9 million in Q4 2022 and bottomed at $5.0 million in Q2 2025.
  • The 5-year median for Total Current Liabilities is $19.9 million (2024), against an average of $18.3 million.
  • The largest annual shift saw Total Current Liabilities soared 237.34% in 2022 before it tumbled 77.77% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $11.2 million in 2021, then soared by 192.82% to $32.9 million in 2022, then plummeted by 31.56% to $22.5 million in 2023, then crashed by 30.55% to $15.6 million in 2024, then plummeted by 66.81% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Total Current Liabilities are $5.2 million (Q3 2025), $5.0 million (Q2 2025), and $19.4 million (Q1 2025).